Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?
Sowa-Staszczak A, Pach D, Stefańska A, Tomaszuk M, Lenda-Tracz W, Mikołajczak R, Pawlak D, Chrzan R, Gilis-Januszewska A, Przybylik-Mazurek E, Hubalewska-Dydejczyk A. Sowa-Staszczak A, et al. Among authors: tomaszuk m. Nucl Med Rev Cent East Eur. 2011;14(2):73-8. doi: 10.5603/nmr.2011.00019. Nucl Med Rev Cent East Eur. 2011. PMID: 22219146 Free article.
Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs).
Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, Tomaszuk M, Kołodziej M, Mikołajczak R, Pawlak D, Hubalewska-Dydejczyk A. Sowa-Staszczak A, et al. Among authors: tomaszuk m. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1669-74. doi: 10.1007/s00259-011-1835-8. Epub 2011 May 11. Eur J Nucl Med Mol Imaging. 2011. PMID: 21559978 Free PMC article. Clinical Trial.
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Pach D, Sowa-Staszczak A, Kunikowska J, Królicki L, Trofimiuk M, Stefańska A, Tomaszuk M, Głowa B, Mikołajczak R, Pawlak D, Jabrocka-Hybel A, Hubalewska-Dydejczyk AB. Pach D, et al. Among authors: tomaszuk m. Radiother Oncol. 2012 Jan;102(1):45-50. doi: 10.1016/j.radonc.2011.08.006. Epub 2011 Aug 30. Radiother Oncol. 2012. PMID: 21885142
Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
Sowa-Staszczak A, Pach D, Kunikowska J, Krolicki L, Stefanska A, Tomaszuk M, Buziak-Bereza M, Mikolajczak R, Matyja M, Gilis-Januszewska A, Jabrocka-Hybel A, Trofimiuk M, Hubalewska-Dydejczyk A. Sowa-Staszczak A, et al. Among authors: tomaszuk m. Endokrynol Pol. 2011;62(5):392-400. Endokrynol Pol. 2011. PMID: 22069099 Free article.
Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?
Sowa-Staszczak A, Chrzan R, Pach D, Stefańska A, Tomaszuk M, Buziak-Bereza M, Kołodziej M, Przybylik-Mazurek E, Hubalewska-Dydejczyk A. Sowa-Staszczak A, et al. Among authors: tomaszuk m. Clin Imaging. 2012 Jul-Aug;36(4):360-4. doi: 10.1016/j.clinimag.2011.11.005. Epub 2012 Jun 8. Clin Imaging. 2012. PMID: 22726975
PRRT as neoadjuvant treatment in NET.
Sowa-Staszczak A, Hubalewska-Dydejczyk A, Tomaszuk M. Sowa-Staszczak A, et al. Among authors: tomaszuk m. Recent Results Cancer Res. 2013;194:479-85. doi: 10.1007/978-3-642-27994-2_27. Recent Results Cancer Res. 2013. PMID: 22918777
Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma.
Sowa-Staszczak A, Pach D, Mikołajczak R, Mäcke H, Jabrocka-Hybel A, Stefańska A, Tomaszuk M, Janota B, Gilis-Januszewska A, Małecki M, Kamiński G, Kowalska A, Kulig J, Matyja A, Osuch C, Hubalewska-Dydejczyk A. Sowa-Staszczak A, et al. Among authors: tomaszuk m. Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):524-31. doi: 10.1007/s00259-012-2299-1. Epub 2012 Dec 7. Eur J Nucl Med Mol Imaging. 2013. PMID: 23224740 Free PMC article.
21 results